Auvelity targets the NMDA and sigma-1 receptors, providing the first non-antipsychotic treatment option for Alzheimer’s patients with agitation.
The post Auvelity becomes first non-antipsychotic approved for Alzheimer’s agitation appeared first on Clinical Trials Arena.
Sen. Adam Schiff (D-Calif.) said Sunday that the Department of Justice (DOJ) sought another grand jury indictment of James Comey because acting Attorney General Todd Blanche …
Sen. Raphael Warnock (D-Ga.) on Sunday slammed the Supreme Court for striking down Louisiana’s congressional maps this week, arguing the national redistricting push is allowing lawmakers …
Jeanine Pirro, the U.S. attorney for the District of Columbia, affirmed Sunday that the bullet that hit a Secret Service agent at last weekend’s White House …
U.S. Africa Command (Africom) on Sunday said two U.S. service members participating in a military exercise missing in Morocco. “The incident remains under investigation and the …